Ad
Search
Generic filters
Filter by content type
Taxonomy terms

XBIO – Xenetic Biosciences Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

2

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 4

Low: 4

High: 4

Total Analysts: 1

Company Profile

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on developing XCART, a personalized Chimeric Antigen Receptor (CAR) T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell non-Hodgkin lymphomas. In addition, the Company is leveraging its drug delivery platform, PolyXen, by partnering with biotechnology and pharmaceutical companies. Its product pipeline includes XCART and ErepoXen, or polysialylated erythropoietin (PSA-EPO). PSA-EPO uses its PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It is designed to reduce the dosing frequency by extending the circulating half-life of therapeutic in the body.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses